All Articles

Amidst FDA warning letters and costly recalls, Integra LifeSciences appoints Topaz Kirlew as its new regulatory chief. It's a critical test of leadership.

Mawer's new fund brings private equity to the masses, but this move from public market safety to private complexity carries risks alongside its rewards.

The recent funding for Luxonis isn't just another AI investment. It’s a validation of edge computing, where intelligent machines see and act in the real world.

A new partnership between Patchwork Labs and Self Storage Manager embeds an AI agent deep into facility software, automating everything from calls to vendors.

NKGen Biotech signals a strategic pivot to Asia, leveraging its novel NK cell therapy, troculeucel, to tap into China's new, accelerated biotech pathways.

Revolution Medicines' zoldonrasib delivers high response rates in trials for RAS G12D pancreatic cancer, offering a beacon of hope against a lethal disease.

YD Bio is expanding its U.S. lab network, but the real story is its strategy: turning diagnostic tests into a vast data engine to power the future of cancer research.

New guidelines for ankle arthritis, a condition hitting younger workers hard, expose major gaps in medical research and a market ripe for innovation.

Neurophet's AI software, now at Raffles Medical, analyzes brain MRIs in minutes, offering a powerful new weapon in the fight against dementia and MS in Asia.

A secretive $36M sole-source contract for Kratos reveals more than just a new missile system; it points to a strategic overhaul of the U.S. defense base.

The new 312-unit Allegra at Cocoa development isn't just new housing; it's a barometer for the economic boom and growing pains of Florida's Space Coast.

With Armando Trivellato at the helm, Omilia aims to shatter automation ceilings in Latin America and Iberia, betting its self-learning AI can transform a market ripe for disruption.

China Yuchai's robust dividend reflects a stellar 2025, but the real story is its deep investment in electric, hybrid, and fuel cell tech for a new era.

Labrador Gold moves into the prolific White Gold District, betting a systematic, tech-driven strategy can unlock value where others left off.

A new partnership aims to build autonomous AI traders. But can these digital agents navigate the complex reality of financial markets and their regulations?

Dole's acquisition of Greenfood's produce arm isn't just expansion; it's a high-tech overhaul of the Nordic supply chain, setting a new bar for the future.

Top advisory firms ISS and Glass Lewis back Shell's takeover of ARC Resources, signaling strong shareholder support for a deal that reshapes Canada's energy map.

Eaton's latest report shows a 40% emissions cut, but the real story is its $2.1B R&D bet, positioning it against rivals in a race to power a greener world.

Lifted Made's Highlandia THC beverage is a top seller in Wisconsin, but its success story is more than a local win—it's a case study in navigating a market on the brink of a federal regulatory cliff.